TGFB1 and head and neck squamous cell carcinoma: These results pave the way for further exploration of the combination of T22-DITOX-H6 treatment with other therapies, such as targeted drugs against TGF-β or FGFR that are also involved in the HNSCC metastatic spread [3,4,5,6,7].